Clinical Trial Update: A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC [Phase 2, Phase 3]

View source ↗

Summary

A pediatric study of vibegron for neurogenic detrusor overactivity in children aged 2 to less than 18 years is currently recruiting, covering Phase 2 and Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity

Drugs mentioned

• Vibegron (vibegron)

Snippet

Sponsor: Urovant Sciences GmbH | Conditions: Neurogenic Detrusor Overactivity | Phase 2, Phase 3 | Status: RECRUITING